# BEACON CRC (NCT02928224)

> Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02928224
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: BRAF V600E-mutant Metastatic Colorectal Cancer
- Interventions: Encorafenib; Binimetinib; Cetuximab; Irinotecan; Folinic Acid; 5-Fluorouracil
- Enrollment: 702
- Primary outcome: (Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)
- Primary outcome: (Safety Lead-in) Number of Participants With Adverse Events (AEs)
- Primary outcome: (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis
- Primary outcome: (Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis
- Primary outcome: (Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis
- Primary outcome: (Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm

## Commentary we found

- X threads: 5
- Podcasts: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=beacon-crc-nct02928224

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02928224", "email": "<work email>"}; the inbox owner confirms by the emailed link.